Novel strategies for treating relapsed/refractory urothelial carcinoma Journal Article
| Authors: | Iyer, G.; Milowsky, M. I.; Bajorin, D. F. |
| Article Title: | Novel strategies for treating relapsed/refractory urothelial carcinoma |
| Abstract: | Advanced urothelial cancer is associated with a poor prognosis and there has been no substantial progress over the past three decades since the development of platinum-based multiagent chemotherapy. Clinical trials evaluating novel agents and combinations including chemotherapeutic drugs, as well as targeted inhibitors, are desperately needed. With a better understanding of the complex molecular alterations that drive urothelial tumorigenesis, new targets for novel therapeutics are being defined. This article will describe the current state of advanced urothelial cancer treatment and provide a comprehensive discussion of novel agents in development. © 2010 Expert Reviews Ltd. |
| Keywords: | cancer survival; treatment response; cancer surgery; unclassified drug; overall survival; clinical trial; constipation; fatigue; neutropenia; review; sorafenib; bevacizumab; cisplatin; doxorubicin; erlotinib; advanced cancer; cancer combination chemotherapy; cancer growth; drug dose reduction; drug efficacy; drug safety; hypertension; monotherapy; gemcitabine; paclitaxel; cancer radiotherapy; methotrexate; recurrent cancer; carboplatin; unindexed drug; metastasis; sensory neuropathy; anemia; bone marrow suppression; bleeding; thrombocytopenia; epidermal growth factor receptor; kidney failure; drug screening; angiogenesis; bladder cancer; cetuximab; ifosfamide; vinblastine; docetaxel; drug dose escalation; febrile neutropenia; fever; lung embolism; cancer regression; drug research; thromboembolism; cardiotoxicity; thrombosis; gefitinib; urinary tract cancer; sepsis; cancer relapse; targeted therapy; weakness; folic acid; taxane derivative; trastuzumab; transitional cell carcinoma; pemetrexed; urothelial cancer; drug tolerance; proteinuria; lapatinib; pralatrexate; granulocytopenia; ixabepilone; eribulin; larotaxel; vinflunine; albumin bound paclitaxel; cyanocobalamin; paclitaxel derivative; tesetaxel; bladder metastasis; kidney dysfunction |
| Journal Title: | Expert Review of Anticancer Therapy |
| Volume: | 10 |
| Issue: | 12 |
| ISSN: | 1473-7140 |
| Publisher: | Taylor & Francis Group |
| Date Published: | 2010-12-01 |
| Start Page: | 1917 |
| End Page: | 1932 |
| Language: | English |
| DOI: | 10.1586/era.10.182 |
| PROVIDER: | scopus |
| PUBMED: | 21110758 |
| PMCID: | PMC3705930 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 20 April 2011" - "CODEN: ERATB" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work